Streetbeat News

Revenues

UPST

Castlelake has announced plans to purchase up to $1.2 billion of consumer installment loans from Upstart. This move is expected to provide Upstart with significant liquidity and could positively impact its financial stability and growth prospects.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:51 pm

FSUMF

Fortescue Metals Group (OTCQX:FSUMF) is facing significant challenges, including falling iron ore prices, executive turnover, infrastructure issues, and declining investor confidence. The company's stock has declined over 25% year-to-date, and major shareholder Capital Group has sold a substantial portion of its shares.

Portfolio Pulse from Stjepan Kalinic

June 20, 2024 | 12:43 pm

OSIS

OSI Systems has received a $10 million order to provide multiple RTT 110 units.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:42 pm

SONN

Sonnet BioTherapeutics has announced the exercise of warrants, resulting in gross proceeds of $3.4 million.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:41 pm

AGRI

AgriFORCE CEO Jolie Kahn and Chairman David Welch have issued a letter to shareholders outlining a transformational year for the company in 2024. The company is focusing on innovation in the agriculture industry, including monetizing its RCS systems and Awaken Grains flour, and expanding into the Carbon Credit and Renewable Energy Credit markets. AgriFORCE has reduced its outstanding debentures and announced a $1 million share repurchase program. The company aims to enhance shareholder value through sustainable practices and new technologies, including blockchain.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:39 pm

ALLO

Allogene Therapeutics has initiated a Phase 2 trial (ALPHA3) to investigate Cemacabtagene Ansegedleucel (Cema-cel) as part of the first-line treatment for patients with large B-cell lymphoma (LBCL) likely to relapse. The trial aims to improve cure rates and incorporates Foresight Diagnostics's CLARITY™ test to identify patients with minimal residual disease (MRD). The trial is expected to complete enrollment in the first half of 2026, with a BLA submission anticipated in 2027.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:38 pm

ZAPP

Zapp EV shares are trading higher following the company's announcement that it expects first customer deliveries of the i300 in Q4 and anticipates selling over 5,000 units by the fiscal year ending September 30, 2025.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:37 pm

FEMY

Femasys has received CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products. This approval allows Femasys to market these products in the European Union, potentially expanding its market reach and revenue.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:34 pm

ZAPP

Zapp EV reported a net loss of $5 million for the first half of the year, an improvement from the $8.6 million loss year-over-year. The company anticipates the first customer deliveries of its i300 model in Q4 and expects to sell over 5,000 units by the fiscal year ending September 30, 2025.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:33 pm

SPY

USA Housing Starts for May decreased by 5.5% compared to the estimated increase of 0.7% and the prior increase of 4.1%.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:31 pm